ClinicalTrials.gg
CompletedNCT01522651HARMONYUpdated Nov 6, 2020Results posted

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

A Phase 2 interventional study of Ranolazine and Dronedarone in Atrial Fibrillation, sponsored by Gilead Sciences. Completed at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
16th of 26
134 · median 164
Started
2012
the only one that year
Phase 2
2 of 26
none open now
Registered
17th of 26
by date
Lead sponsor
1 of 26
Gilead Sciences

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 16th largest by enrollment, is the only one that started in 2012, is one of 2 in phase 2, and was the 17th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
  • Ranolazine
  • Dronedarone
  • Dual Chamber Pacemakers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females aged 18 years and older
  • Have the ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • History of PAF documented within the prior 12 months

    • Patients with PAF undergoing cardioversion greater than 4 weeks prior to Screening are eligible
  • Implanted (at least 3 months prior to Screening) dual chamber programmable pacemakers with AF detection capabilities
  • AFB ≥ 1% and ≤ 70% between the last clinic evaluation and Screening (minimum of 1 month observation period) and AFB ≥ 2% and ≤ 70% during the Run in period
  • Sexually active females of must agree to utilize effective methods of during heterosexual intercourse throughout the treatment period and for 14 days following discontinuation of the study medication

Key Exclusion Criteria:

Disease - specific:

  • Persistent AF or Permanent AF
  • History of atrial flutter or atrial tachycardia without successful ablation
  • Other acutely reversible causes of AF, including but not limited to: hyperthyroidism, pericarditis, myocarditis, or pulmonary embolism
  • (NYHA) Class III and IV heart failure or NYHA Class II heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic within 4 weeks prior to Screening.
  • Recent history of (LVEF) \< 40%
  • Myocardial infarction, unstable angina, or coronary artery bypass graft (CABG) surgery within three months prior to Screening or percutaneous coronary intervention (PCI) within 4 weeks prior to Screening
  • valvular disease in the opinion of the Investigator
  • Stroke within 3 months prior to Screening
  • History of serious ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation) within 4 weeks prior to Screening
  • Family history of long syndrome
  • Corrected QT interval (QTc) ≥ 500 msec (Bazett) at Screening if in sinus rhythm (SR). If in AF, evidence of QTc ≥ 500 msec (Bazett) within 4 weeks prior to Screening
  • Prior heart transplant
  • Cardiac ablation within 4 months prior to Screening, or planned ablation during the course of the study

Concomitant medications/food

  • Need for concomitant treatment during the trial, with drugs or products that are strong inhibitors of cytochrome P450 3A (), or inducers of CYP3A

    • Such medications should be discontinued 5-half lives prior to the Run-in period
  • Use of grapefruit juice or Seville orange juice during the study
  • Use of Class I and Class III antiarrhythmic drugs other than amiodarone within 5-half lives prior to the Run-in period
  • Use of amiodarone within 3 months prior to Screening
  • Use of drugs that prolong the QT interval
  • Previous use of ranolazine or dronedarone within 2 months prior to screening
  • Prior use of ranolazine or dronedarone which was discontinued for safety or tolerability
  • Use of dabigatran during the study
  • Use of digitalis preparations (eg, digoxin) during the study
  • Use of a greater than 1000 mg total daily dose of metformin during the study

Laboratory tests:

  • Hypokalemia (serum potassium \< 3.5 mEq/L) at Screening that cannot be corrected to a level of potassium ≥ 3.5 mEq/L prior to randomization
  • Moderate and severe hepatic impairment (ie, Class B and C), abnormal liver function test defined as (ALT), aspartate aminotransferase (AST), or > 2 x (ULN) at Screening
  • Severe renal impairment defined as ≤ 30 mL/min at Screening

Others:

  • Females who are pregnant or are breastfeeding
  • In the judgment of the Investigator, any clinically-significant ongoing medical condition that might jeopardize the individual's safety or interfere with the study, including participation in another clinical trial within the previous 30 days using a therapeutic modality which could have potential residual effects that might confound the results of this study
  • Any device-related technical issue which in the judgment of the investigator would disrupt adequate data collection or interpretation (eg, anticipated pulse generator change or lead revision)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
134 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Ranolazine placebo plus dronedarone placebo for 12 weeks.

    Drug: Ranolazine placebo · Drug: Dronedarone placebo

  • Experimental
    Ranolazine 750 mg

    Ranolazine 750 mg plus dronedarone placebo for 12 weeks.

    Drug: Ranolazine · Drug: Dronedarone placebo

  • Experimental
    Dronedarone 225 mg

    Ranolazine placebo plus dronedarone 225 mg for 12 weeks.

    Drug: Dronedarone · Drug: Ranolazine placebo

  • Experimental
    Ranolazine 750 mg + Dronedarone 225 mg

    Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.

    Drug: Ranolazine · Drug: Dronedarone

  • Experimental
    Ranolazine 750 mg + Dronedarone 150 mg

    Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.

    Drug: Ranolazine · Drug: Dronedarone

Interventions

  • Tablets administered orally twice daily.

    Also known as: Ranexa®

  • Capsule administered orally twice daily

  • DrugRanolazine placebo

    Tablets administered orally twice daily.

  • DrugDronedarone placebo

    Capsules administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Atrial Fibrillation Burden (AFB) at Baseline

    AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated.

    Time frame: Baseline

  2. Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12

    AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. Geometric mean is the mean of log-transformed AFB exponentiated.

    Time frame: Baseline; Week 12

  3. Absolute Change From Baseline in AFB by Week 12

    AFB is defined as the total time a participant is in AT/AF expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment.

    Time frame: Baseline; Week 12

Secondary outcomes

  1. Percentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB

    AFB was defined as the total time a participant was in AT/AF expressed as a percentage of total recording time.

    Time frame: Week 12

07

Results

Posted Nov 6, 2020

Participant flow

Participants were enrolled at study sites in Germany, Israel, Italy, Netherlands, Poland, and the United States. The first participant was screened on 24 January 2012. The last study visit occurred on 10 March 2014.

Participant flow — Overall Study
MilestonePlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mg
Started2627262827
Completed1719222021
Not completed98486
Withdrew: Adverse event34454
Withdrew: Cardioversion10000
Withdrew: Device malfunction01000
Withdrew: Investigator's discretion01000
Withdrew: Protocol violation30000
Withdrew: Reason not specified00010
Withdrew: Participant non-compliance10000
Withdrew: Withdrew consent11011
Withdrew: Randomized but never treated01011

Outcome measures

PrimaryAtrial Fibrillation Burden (AFB) at Baseline

AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated.

Time frame:
Baseline
Reported as:
Geometric mean · Percentage of total recording time
Atrial Fibrillation Burden (AFB) at Baseline
Percentage of total recording timePlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mg
Atrial Fibrillation Burden (AFB) at Baseline12.7 ± 2.2110.8 ± 2.7011.6 ± 2.4711.7 ± 2.4011.7 ± 2.04
PrimaryPercent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12

AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. Geometric mean is the mean of log-transformed AFB exponentiated.

Time frame:
Baseline; Week 12
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12
percent changePlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mg
Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12-5.9 ± 18.00-23.0 ± 21.173.5 ± 15.68-59.1 ± 10.47-45.5 ± 10.73
Statistical analysis
  • Placebo vs Ranolazine 750 mg · ANCOVA · p = 0.493 (An equal-slopes analysis of covariance (ANCOVA) model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.) · Percentage difference: -19.8 · 95% CI -57.5 to 51.5
  • Placebo vs Dronedarone 225 mg · ANCOVA · p = 0.780 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.) · Percentage difference: 8.8 · 95% CI -40.2 to 98.2
  • Placebo vs Ranolazine 750 mg + Dronedarone 225 mg · ANCOVA · p = 0.008 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.) · Percentage difference: -57.0 · 95% CI -76.8 to -20.1
  • Placebo vs Ranolazine 750 mg + Dronedarone 150 mg · ANCOVA · p = 0.072 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.) · Percentage difference: -42.6 · 95% CI -68.7 to 5.2
  • Ranolazine 750 mg vs Dronedarone 225 mg · ANCOVA · p = 0.315 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.)
  • Ranolazine 750 mg vs Ranolazine 750 mg + Dronedarone 225 mg · ANCOVA · p = 0.049 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.)
  • Ranolazine 750 mg vs Ranolazine 750 mg + Dronedarone 150 mg · ANCOVA · p = 0.275 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.)
  • Dronedarone 225 mg vs Ranolazine 750 mg + Dronedarone 225 mg · ANCOVA · p = 0.002 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.)
  • Dronedarone 225 mg vs Ranolazine 750 mg + Dronedarone 150 mg · ANCOVA · p = 0.028 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.)
  • Ranolazine 750 mg + Dronedarone 225 mg vs Ranolazine 750 mg + Dronedarone 150 mg · ANCOVA · p = 0.334 (An equal-slopes ANCOVA model was fitted to log-transformed AFB over 12 weeks, with baseline AFB as the covariate. AFB values \< 1% (\> 99%) were set to 1% (99%) before transformation.)
PrimaryAbsolute Change From Baseline in AFB by Week 12

AFB is defined as the total time a participant is in AT/AF expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment.

Time frame:
Baseline; Week 12
Reported as:
Mean · percentage of total recording time
Absolute Change From Baseline in AFB by Week 12
percentage of total recording timePlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mg
Baseline16.8 ± 3.6617.3 ± 3.7419.1 ± 4.1416.8 ± 3.1116.7 ± 3.52
Absolute Change From Baseline in AFB by Week 124.6 ± 3.19-3.1 ± 2.175.6 ± 2.65-4.7 ± 3.24-3.9 ± 3.11
SecondaryPercentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB

AFB was defined as the total time a participant was in AT/AF expressed as a percentage of total recording time.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB
percentage of participantsPlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mg
≥ 30% Reduction From Baseline AFB22.250.021.745.054.5
≥ 50% Reduction From Baseline AFB16.722.213.045.054.5
≥ 70% Reduction From Baseline AFB11.116.78.745.027.3

Adverse events

Collected over Adverse Events: First dose date up to the last dose date (maximum 102 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/26 (0%)1/26 (3.8%)9/26 (34.6%)
Ranolazine 750 mg0/26 (0%)7/26 (26.9%)15/26 (57.7%)
Dronedarone 225 mg0/26 (0%)2/26 (7.7%)14/26 (53.8%)
Ranolazine 750 mg + Dronedarone 225 mg0/27 (0%)5/27 (18.5%)12/27 (44.4%)
Ranolazine 750 mg + Dronedarone 150 mg0/26 (0%)1/26 (3.8%)14/26 (53.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mg
Atrial fibrillationCardiac disorders0/263/261/260/271/26
Atrial flutterCardiac disorders1/260/260/260/270/26
Cardiac failure congestiveCardiac disorders0/260/261/260/270/26
TachyarrhythmiaCardiac disorders0/260/261/260/270/26
Gastrointestinal haemorrhageGastrointestinal disorders0/261/260/260/270/26
International normalised ratio increasedInvestigations0/261/260/261/270/26
PresyncopeNervous system disorders0/261/260/260/270/26
HypertensionVascular disorders0/261/260/260/270/26
VertigoEar and labyrinth disorders0/260/260/261/270/26
Chest painGeneral disorders0/260/260/261/270/26
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mg
Atrial fibrillationCardiac disorders2/260/264/261/272/26
ConstipationGastrointestinal disorders0/261/261/261/274/26
VertigoEar and labyrinth disorders0/263/260/260/271/26
Abdominal painGastrointestinal disorders0/260/263/262/270/26
NauseaGastrointestinal disorders0/263/261/262/271/26
FatigueGeneral disorders0/263/260/262/271/26
Oedema peripheralGeneral disorders0/260/263/262/270/26
Urinary tract infectionInfections and infestations3/261/262/260/270/26
DizzinessNervous system disorders1/263/262/260/272/26
HypotensionVascular disorders0/260/260/263/271/26

Baseline characteristics

The Safety Analysis Set included participants who received ≥ 1 dose of study drug (ranolazine/placebo tablets or dronedarone/placebo capsules).

Age, Continuous
Age, Continuous(years)PlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mgTotal
Mean72 ± 8.470 ± 10.875 ± 7.871 ± 7.173 ± 9.472 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mgTotal
Female131616121168
Male131010151563
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mgTotal
Hispanic or Latino200316
Not Hispanic or Latino2225262425122
Unknown or Not Reported210003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mgTotal
American Indian or Alaska Native000000
Asian000011
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White2626262725130
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)PlaceboRanolazine 750 mgDronedarone 225 mgRanolazine 750 mg + Dronedarone 225 mgRanolazine 750 mg + Dronedarone 150 mgTotal
Germany5484223
Israel5616624
Italy000101
Netherlands000011
Poland101211111559
United States6465223
08

Study locations

50 sites
  • Investigational Site
    Beverly Hills, California 90211, United States
  • Investigational Site
    Newport Beach, California 92663, United States
  • Investigational Site
    San Francisco, California 94143, United States
  • Investigational Site
    Aurora, Colorado 80012, United States
  • Investigational Site
    Washington, District of Columbia 20010, United States
  • Investigational Site
    Lakeland, Florida 33805, United States
  • Investigational Site
    Takoma Park, Maryland 20912, United States
  • Investigational Site
    Towson, Maryland 21204, United States
  • Investigational Site
    Utica, New York 13501, United States
  • Investigational Site
    Cleveland, Ohio 44106, United States
  • Investigational Site
    Warwick, Rhode Island 02886, United States
  • Investigational Site
    Houston, Texas 77030, United States
  • Investigational Site
    Murray, Utah 84107, United States
  • Investigational Site
    Seattle, Washington 98122, United States
  • Investigational Site
    Wausau, Wisconsin 54401, United States
  • Investigational Site
    München, Bayern 81377, Germany
  • Investigational Site
    Würzburg, Bayern 97080, Germany
  • Investigational Site
    Bonn, Nordrhein-westfalen 53105, Germany
  • Investigational Site
    Coburg, 96450, Germany
  • Investigational Site
    Frankfurt, 60594, Germany
  • Investigational Site
    Göttingen, 37075, Germany
  • Investigational Site
    Ingolstadt, 85049, Germany
  • Investigational Site
    Lubeck, D23538, Germany
  • Investigational Site
    Ashkelon, Ashqelon 78287, Israel
  • Investigational Site
    Afula, Zefat 18101, Israel
  • Investigational Site
    Hadera, 38100, Israel
  • Investigational Site
    Haifa, 31096, Israel
  • Investigational Site
    Holon, 58100, Israel
  • Investigational Site
    Jerusalem, 91031, Israel
  • Investigational Site
    Nahariya, 22100, Israel
  • Investigational Site
    Rehovot, 76100, Israel
  • Investigational Site
    Como, 22020, Italy
  • Investigational Site
    Firenze, 50134, Italy
  • Investigational Site
    Maastricht, Limburg 6229 HX, Netherlands
  • Investigational Site
    Groningen, 9700 RB, Netherlands
  • Investigational Site
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Investigational Site
    Lodz, Lodzkie 90-553, Poland
  • Investigational Site
    Kraków, Malopolskie 31-501, Poland
  • Investigational Site
    Warsaw, Mazowieckie 01-211, Poland
  • Investigational Site
    Warsaw, Mazowieckie 04-628, Poland
  • Investigational Site
    Bialystok, Podlaskie 15-276, Poland
  • Investigational Site
    Gdansk, Pomorskie 80-219, Poland
  • Investigational Site
    Sopot, Pomorskie 81-717, Poland
  • Investigational Site
    Katowice, Slaskie 40-635, Poland
  • Investigational Site
    Zabrze, Slaskie 41-800, Poland
  • Investigational Site
    Poznań, Wielkopolskie 61-848, Poland
  • Investigational Site
    Szczecin, Zachodniop 70-203, Poland
  • Investigational Site
    Lodz, 91-425, Poland
  • Investigational Site
    Warszawa, 02-097, Poland
  • Investigational Site
    London, England SE5 9RS, United Kingdom
09

References and documents

Publications

  • Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba W, Rosero S, Kowey P; HARMONY Investigators. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1048-56. doi: 10.1161/CIRCEP.115.002856. Epub 2015 Jul 30. PubMed 26226999 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Mar 2014, 25 months.

Results were first posted in Nov 2020, 6 years 7 months after primary completion. A results delay was requested in Aug 2014.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2012
First posted
Jan 31, 2012
StartActual
Jan 24, 2012
Primary completionActual
Mar 10, 2014
CompletionActual
Mar 10, 2014
Results delay requested
Aug 7, 2014
Results first posted
Nov 6, 2020
Last update
Nov 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01522651
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 31, 2012
Start date
Jan 24, 2012
Primary completion
Mar 10, 2014
Completion
Mar 10, 2014
Results posted
Nov 6, 2020
Last update
Nov 6, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ranolazine · Dronedarone

Start the discussion